目的探討腦立清膠囊聯(lián)合培哚普利吲達(dá)帕胺片治療老年原發(fā)性高血壓的療效觀(guān)察。方法選取2018年4月-2020年4月在青島市第九人民醫(yī)院內(nèi)科住院治療的124例老年原發(fā)性高血壓患者，根據(jù)治療方法將124例老年原發(fā)性高血壓患者分為對(duì)照組（62例）和觀(guān)察組（62例）。對(duì)照組患者口服培哚普利吲達(dá)帕胺片，1片/次，1次/d。觀(guān)察組患者在對(duì)照組的基礎(chǔ)上給予口服腦立清膠囊，3粒/次，2次/d。兩組連續(xù)服用7 d。觀(guān)察兩組患者的臨床療效，同時(shí)比較兩組治療前后的臨床癥狀緩解時(shí)間、血壓水平以及血清白細(xì)胞介素1（IL-1）、腫瘤壞死因子α（TNF-α）、高敏C反應(yīng)蛋白（hs-CRP）、同型半胱氨酸（Hcy）、血管內(nèi)皮素（ET-1）水平。結(jié)果治療后，觀(guān)察組臨床總有效率為98.39%，顯著高于對(duì)照組的85.48%（P<0.05）。治療后，觀(guān)察組患者的臨床癥狀頭痛、眩暈、胸悶、心悸緩解時(shí)間均短于對(duì)照組（P<0.05）。治療后，兩組收縮壓（SBP）、舒張壓（DBP）水平均顯著降低，觀(guān)察組患者SBP、DBP水平顯著低于對(duì)照組（P<0.05）。治療后，兩組IL-1、hs-CR、TNF-α、Hcy、ET-1水平均顯著降低（P<0.05）；且觀(guān)察組患者血清因子水平均低于對(duì)照組（P<0.05）。結(jié)論腦立清膠囊與培哚普利吲達(dá)帕胺片聯(lián)合治療老年原發(fā)性高血壓，臨床效果較為顯著，能夠?qū)颊叩难獕河忻黠@改善，不良反應(yīng)率低，安全可靠，值得在臨床推廣。

Objective To investigate the efficacy of Naoliqing Capsules combined with Perindopril and Indapamide Tablets in treatment of senile essential hypertension. Methods A total of 124 elderly patients with essential hypertension who were hospitalized in the Department of Internal Medicine of Qingdao Ninth People's Hospital from April 2018 to April 2020 were selected. According to the treatment methods, the 124 elderly patients with essential hypertension were divided into control group (62 cases) and observation group (62 cases). Patients in the control group were po administered with Perindopril and Indapamide Tablets, 1 tablet/time, once daily. Patients in the observation group were po administered with Naoliqing Capsules on the basis of control group, 3 grains/time, twice daily. Both groups were treated for 7 days. The clinical efficacy of two groups was observed, and the clinical symptom remission time, blood pressure, serum levels of IL-1, TNF-α, hs-CRP, Hcy, and ET-1 before and after treatment were compared between two groups. Results After treatment, the total clinical effective rate of observation group was 98.39%, which was significantly higher than 85.48% of control group (P < 0.05). After treatment, the relief time of clinical symptoms such as headache, vertigo, chest tightness, and palpitation in the observation group was shorter than that in the control group (P < 0.05). After treatment, the SBP and DBP levels in two groups were significantly decreased, and the SBP and DBP levels in observation group were significantly lower than control group (P < 0.05). After treatment, the levels of IL-1, hs-CRP, TNF-α, Hcy, and ET-1 in two groups were significantly decreased (P < 0.05), and serum factor levels in observation group were lower than those in control group (P < 0.05). Conclusion Naoliqing Capsules combined with Perindopril and Indapamide Tablets in treatment of elderly patients with essential hypertension has a significant clinical effect, can significantly improve the patient's blood pressure, low adverse reaction rate, safe and reliable, worthy of clinical promotion.

R972